Zimbabwe has turned down a major American healthcare agreement valued at 367 million US dollars (272 million pounds) over five years due to Washington's insistence on confidential biological samples.
This rejection was revealed following a government memo dated December was disclosed, which showed Head of State Emmerson Mnangagwa believed the deal was "lopsided".
An official representative has since clarified that the United States was requesting genetic material for research and commercial purposes but refused to share the resulting advantages from any future treatments.
"We must now begin the difficult and regrettable process of ending our support in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont in a statement.
Her embassy noted the US had furnished more than $1.9bn in health funding to Zimbabwe over the last two decades.
A doctors' association in Zimbabwe has urged further talks to find a deal acceptable to both sides so the country's vital HIV programme can be sustained.
Wider Context
Zimbabwe's decision follows a comparable case in neighbouring Kenya, where a court blocked a related deal with the US following legal challenges were raised about the security of citizens' health data.
Since resuming office recently, US President Donald Trump has drastically cut foreign aid and closed the key foreign aid agency.
USAID had managed assistance for the US government, but Trump claimed its expenditure was "inefficient" and his government was pursuing government-to-government deals to enhance openness and responsibility.
Based on reports, 16 African countries have to date signed these new agreements, representing more than $18.3bn in committed funds.
Details of the Rejected Deal
The money for Zimbabwe was intended to supported "HIV/Aids treatment and prevention, tuberculosis, malaria, maternal and child health, and disease outbreak preparedness.
"We are confident this cooperation could have provided extraordinary benefits for Zimbabwean communities, especially the 1.2 million presently receiving antiretroviral therapy through American-funded programmes," Tremont commented.
However, government spokesperson Nick Mangwana said the proposed deal was "unequal".
"The proposal required Zimbabwe to surrender its biological resources and data for a long time, with no corresponding promise of benefiting from any scientific breakthroughs – such as vaccines, diagnostics, or treatments – that might be developed from that provided information," he stated.
"Put simply, our country would supply the basic resources for scientific discovery without any certainty that the resulting innovations would be accessible to our population if a new pandemic emerge."
Sovereignty and Global Health
Mangwana further noted that the US's withdrawal from the World Health Organization (WHO) and its pursuit of bilateral deals were undermining systems previously set up via the global health agency.
Mangwana gave as an example its Pathogen Access and Benefit Sharing system designed to deal with future pandemics.
"This mechanism is designed to guarantee that when a country provides its data, the benefits – including vaccines and treatments – are shared equitably, not monopolised exclusively by those with the resources to create them."
These objections regarding the US deal "should not be misconstrued as hostility towards the US," he added.
"We are open to ongoing discussions with our American counterparts on how subsequent collaboration might be structured in a way that respects the independence and dignity of each country."
Medical Community Response
Medical experts stated it acknowledged the government's concerns, but urged that talks need to persist considering much of the country's HIV programmes depended on international support.
"In cases where specific concerns arise, including those relating to information security or agreement terms, these can often be addressed via technical clarification and mutually agreed protections," the group said.
This impasse highlights the ongoing debate between receiving much-needed international aid and safeguarding national sovereignty in an increasingly interconnected world.